Liquidia Co. (NASDAQ:LQDA – Get Rating) was the recipient of a significant decrease in short interest in June. As of June 15th, there was short interest totalling 1,170,000 shares, a decrease of 24.5% from the May 31st total of 1,550,000 shares. Based on an average trading volume of 1,020,000 shares, the days-to-cover ratio is presently 1.1 days.
Shares of LQDA traded down $0.12 during trading hours on Monday, reaching $4.24. 13,722 shares of the company traded hands, compared to its average volume of 806,423. The stock has a market capitalization of $272.82 million, a PE ratio of -5.30 and a beta of 0.29. Liquidia has a fifty-two week low of $2.25 and a fifty-two week high of $7.78. The stock has a fifty day simple moving average of $4.81 and a 200 day simple moving average of $5.62.
Liquidia (NASDAQ:LQDA – Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). The company had revenue of $3.49 million during the quarter, compared to analyst estimates of $3.26 million. During the same quarter in the prior year, the firm posted ($0.21) earnings per share. On average, equities analysts forecast that Liquidia will post -0.97 EPS for the current fiscal year.
A number of brokerages have recently weighed in on LQDA. Bank of America began coverage on Liquidia in a research report on Thursday, May 26th. They issued a “buy” rating and a $12.00 price target for the company. BTIG Research began coverage on Liquidia in a research report on Tuesday, May 31st. They issued a “buy” rating and a $14.00 price target for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Liquidia currently has a consensus rating of “Moderate Buy” and an average price target of $12.00.
In other news, Director Caligan Partners Lp purchased 1,764,705 shares of the company’s stock in a transaction dated Monday, April 18th. The stock was acquired at an average price of $5.10 per share, for a total transaction of $8,999,995.50. Following the completion of the transaction, the director now directly owns 10,093,123 shares in the company, valued at approximately $51,474,927.30. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Robert A. Lippe purchased 29,628 shares of the company’s stock in a transaction dated Tuesday, May 24th. The stock was purchased at an average price of $3.38 per share, with a total value of $100,142.64. Following the transaction, the insider now owns 90,692 shares of the company’s stock, valued at $306,538.96. The disclosure for this purchase can be found here. Insiders acquired 2,065,133 shares of company stock valued at $10,395,378 in the last quarter. 29.50% of the stock is currently owned by company insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its stake in Liquidia by 674.3% in the 1st quarter. Bank of America Corp DE now owns 13,473 shares of the company’s stock worth $97,000 after buying an additional 11,733 shares during the last quarter. Jane Street Group LLC acquired a new stake in Liquidia in the 1st quarter worth about $762,000. Royal Bank of Canada boosted its stake in Liquidia by 144.7% in the 1st quarter. Royal Bank of Canada now owns 59,194 shares of the company’s stock worth $425,000 after buying an additional 35,007 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Liquidia by 535.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 115,994 shares of the company’s stock worth $832,000 after buying an additional 97,754 shares during the last quarter. Finally, Prelude Capital Management LLC acquired a new stake in Liquidia in the 1st quarter worth about $275,000. 27.68% of the stock is currently owned by institutional investors and hedge funds.
About Liquidia (Get Rating)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension.